Michael S. Kegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael S. Kegel has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adam Williams
Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
1 shared publication - Arya B. Ökten
Department of Immunobiology, Yale School of Medicine, New Haven, CT 06510, USA
1 shared publication - Ashwin N. Skelly
Department of Medicine, Perelman School of Medicine, University of Pennsylvania
1 shared publication - Brieyanna C. McWilliams
Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
1 shared publication - Christiane E. Wobus
Department of Microbiology and Immunology, University of Michigan Medical School
1 shared publication - Craig Wilen
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
1 shared publication
Latest Publications
- 24 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (855) , eaeb4878
IgA is necessary and sufficient to prevent norovirus infection in mice
Human norovirus is the leading cause of viral gastroenteritis, yet effective vaccines and therapeutics remain elusive. Using murine norovirus as a model, we found that mucosal immunoglobulin A (IgA) is both necessary and sufficient for protection against infection, whereas CD8 + T cells are dispensable. Robust intestinal IgA production requires at least 4 weeks of enteric infection, consistent with kinetics of human norovirus RNA clearance. Systemic vaccination elicits high titers of neutralizing serum IgG but fails to prevent enteric norovirus infection, phenocopying a recent human norovirus vaccine failure. In contrast, prophylactic delivery of dimeric anti-norovirus IgA via mRNA lipid nanoparticles confers sterilizing immunity. Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.
- 24 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (855) , eaeb4878
IgA is necessary and sufficient to prevent norovirus infection in mice
Human norovirus is the leading cause of viral gastroenteritis, yet effective vaccines and therapeutics remain elusive. Using murine norovirus as a model, we found that mucosal immunoglobulin A (IgA) is both necessary and sufficient for protection against infection, whereas CD8 + T cells are dispensable. Robust intestinal IgA production requires at least 4 weeks of enteric infection, consistent with kinetics of human norovirus RNA clearance. Systemic vaccination elicits high titers of neutralizing serum IgG but fails to prevent enteric norovirus infection, phenocopying a recent human norovirus vaccine failure. In contrast, prophylactic delivery of dimeric anti-norovirus IgA via mRNA lipid nanoparticles confers sterilizing immunity. Together, these findings define a critical role for mucosal IgA in norovirus protection and identify IgA-based treatments as a therapeutic approach for human norovirus.